We have very little data that the EU would except. Our last P3 was US based and as such the EU would first want FDA approval before considering that data for approval. Same as we see with Takeda were they first got EU approval and now are doing trials in the US.
Cell Therapy News/Articles, page-16742
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.32 |
Change
-0.025(1.86%) |
Mkt cap ! $1.507B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.35 | $1.31 | $2.699M | 2.040M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34995 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 10374 | 2 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |